Metabolomic Footprints of Lethal Versus Indolent Prostate Cancer

Jing Ma,Clary B. Clish,Jorge E. Chavarro,Weiliang Qiu,Yin Cao,Yan Meng,Changzheng Yuan

2014-01-01

Abstract:: The current study is to use a targeted, LC-MS-based metabololite profiling platform to measure and compare metabolic profiles of prediagnostic blood samples collected from men subsequently diagnosed with prostate cancer (PCa) and sample of men who remained cancer-free in a prospective cohort of the Physicians' Health Study (PHS). And test whether the metabolomics profiling are related to 1) metastatic PCa at diagnosis as compared with normal controls; and 2) among PCa patients, related developing fatal outcome as compared with long-term survivors. We will also assess whether these associations are independent of the known metabolic risk factors (overweight/obese, insulin marker C-peptide, insulin-like growth factor I (IGF-I), IGF binding protein 3, (IGFBP-3), and adiponectin) as well as the clinical characteristics defined as the D'Amico risk. In the original protocol, we plan to measure samples of PCa cases from both HPFS and PHS. During the first year, we were working on informative case and control selection and during this period of time, the HPFS team has received separate grant for metabolomics measurement. We, therefore, amended our study population to focus only on the PHS samples but stick to our original planned 400 study participants. Based on the available samples, we utilized matched case control design to select the blood samples to be measured. The selected blood samples are currently being pooled in the blood lab and due to a big queue of work load at the blood lab, we are waiting for blood sample aliquating and boxing.